PDR Drug Update - June 2021

PDR MEMBER LOGIN:

Not a Member? Register Now

Email or Username

Password

Remember me

Forgot your password?

PDR Search

type drug name here... Required field
Home /

PDR Drug Update /

June 2021 /

Labeling Updates

email share print Close window

Email this page

Send the page "" to a friend, relative, colleague or yourself.

Your Name

Recipient's Email
Separate multiple email address with a comma

Message

We do not record any personal information entered above.

Thank you. Your email has been sent.

Share this page

Facebook Twitter Linkedin
Advertisement
eDrug Update - June 2021

Recent FDA Approvals

Qelbree Capsules (viloxazine hydrochloride), Supernus Pharmaceuticals, Inc.

Labeling Updates

K e y
Boxed Warning
Other Warnings^*

*Warnings and Precautions; Adverse Reactions; Drug Interactions; and Contraindications
Updates to Indications/Dosage
Other Updates^{^†}

^†Other labeling changes; added to PDR database

				Linzess (linaclotide)
				Qelbree Capsules (viloxazine hydrochloride) - RECENT FDA APPROVAL

Skyrizi (risankizumab-rzaa)